ProShares Ultra Nasdaq Biotechnology (BIB)

NASDAQ: BIB · IEX Real-Time Price · USD
-0.39 (-0.68%)
Jan 27, 2022 12:56 PM EST - Market open
Expense Ratio0.95%
PE Ration/a
Shares Out2.20M
Dividend (ttm)n/a
Dividend Yieldn/a
Ex-Dividend DateSep 21, 2010
1-Year Return-40.61%
Previous Close57.66
Day's Range57.11 - 59.24
52-Week Low54.46
52-Week High54.46
Inception DateApr 8, 2010

About BIB

The fund invests in financial instruments that ProShare Advisors believes, in combination, should produce daily returns consistent with the fund's investment objective. The index is a modified capitalization weighted index that includes securities of Nasdaq listed companies that are classified as either biotechnology or pharmaceutical. The fund is non-diversified.

Asset ClassEquity
RegionNorth America
Stock ExchangeNASDAQ
Ticker SymbolBIB
Index TrackedNASDAQ Biotechnology Index

Top 10 Holdings

65.95% of assets
NASDAQ Biotechnology Index SWAP Citibank NA N/A13.91%
NASDAQ Biotechnology Index SWAP Goldman Sachs International N/A10.76%
NASDAQ Biotechnology Index SWAP Societe Generale N/A10.19%
NASDAQ Biotechnology Index SWAP Bank of America NA N/A8.85%
NASDAQ Biotechnology Index SWAP UBS AG N/A5.43%
Gilead SciencesGILD3.83%
Regeneron PharmaceuticalsREGN2.90%
Vertex PharmaceuticalsVRTX2.61%
View More Holdings


Ex-DividendAmountPay Date
Dec 23, 2021$0.000Dec 31, 2021
Sep 22, 2021$0.000Sep 29, 2021
Jun 22, 2021$0.000Jun 29, 2021
Mar 23, 2021$0.000Mar 30, 2021
Mar 23, 2016$0.000Apr 1, 2016
Full Dividend History


Cap-Weighting Crucial When Indexing Biotech

The biotechnology industry is a bifurcated space. In one corner, you have nascent, small-cap companies that don't yet have steady revenue streams because their new drug or treatment is still in developm...

Other symbols:BISIBBQ
2 days ago - ETF Trends

How to Invest in Biotech in 2022

It's been a hard year for a lot of the biotech industry, with many hedge funds ending the year with significant losses, but there have been a number of shining stars that are expected to continue to off...

1 month ago - ETF Trends

Take a Look at the Top-Performing Biotech ETFs YTD

The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.

3 months ago - Zacks Investment Research

Could Biotech ETFs Get Another Boost From JNJ News?

This has been a pivotal week for biotech news, as Johnson & Johnson said Wednesday that a booster shot of its COVID-19 vaccine generated a promising immune response in early stage clinical trials. This ...

Other symbols:PBE
5 months ago - ETF Trends

Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs

Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.

Other symbols:LABU
5 months ago - Zacks Investment Research

Pfizer-BioNTech COVID-19 Vaccine Garners Full FDA Approval

The FDA has officially given full approval to Pfizer and BioNTech for their COVID-19 vaccine, potentially making way for more approvals and more vaccine mandates, reports CNBC. It is a move that officia...

Other symbols:BNTXPFE
5 months ago - ETF Trends

Biotech ETFs Are Already Benefitting from Pfizer Vaccine's Full Approval

There could be big gains ahead for biotech ETFs, as the Food and Drug Administration on Monday fully approved the Pfizer and BioNTech coronavirus vaccine, making it the first vaccine in the U.S. to be a...

Other symbols:PBE
5 months ago - ETF Trends

As Covid Cases Mutate, the Biotech Industry Works to Keep Up

As the Delta variant sweeps across the globe, pharmaceutical and biotech companies are working to ensure vaccines continue to cover the population, as well as working on booster doses that can adapt to ...

6 months ago - ETF Trends

Top-Performing Biotechnology ETFs Amid Coronavirus Outbreak

From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.

Other symbols:ARKGIDNAXBI
1 year ago - Zacks Investment Research

4 Best-Performing Leveraged ETF Areas of Last Week

Last week witnessed a tug-of-war between bulls and bears.

1 year ago - Zacks Investment Research